FDA Approves New Once-a-day Three Drug Combination Tablet

The key to successful HIV drug treatment is adhering to the prescribed combination each and everyday. To that end, drug manufacturers Gilead Sciences and Bristol-Myer-Squibb have gained FDA approval for their joint venture; the first once-a-day three drug combination tablet for the treatment of HIV. Atripla is the name of the new tablet that combines the existing HIV drugs Sustiva (efavirenz), Emtriva (emtricitabine) and Viread (tenofovir disoproxil fumarate). The approval of this drug provides HIV care providers with the first true once per day therapy. The importance of adherence to therapies can never be overstated and with the new drug Atripla, adherence has become much easier. Atripla should be available in pharmacies within a month. Consult your physician if you think Atripla can help you.